The standard of care is to offer androgen deprivation therapy (ADT) to men with prostate cancer who have a rising prostate specific antigen (PSA) after an attempt to cure their cancer with primary therapy that has failed (PSA relapse) or in men who are considered not suitable for curative treatment. The question is what is [...]
In a recently published commentary about the optimal type of multi-modal hormone therapy for Gleason grade 4 and 5 prostate cancer the author addressed the discordance between results of several randomized trials evaluating survival benefit of continuous androgen deprivation therapy in men with high-risk disease. The study found that after combining data from multiple trials, [...]
Making treatment decisions once you have been diagnosed with prostate cancer is difficult. Often, it is impossible to accurately and reliably be able to predict the eventual course of the cancer. Prostate cancer, besides being one of the slower growing cancers, is also one of the deadliest. So good, informed decisions are vital. The original [...]
The possibility of having incontinence as a side effect from all of the primary prostate cancer treatments is significant. Incontinence is not an either or thing as the degree of incontinence varies from individual to individual. Those men having significant levels of inconvenience find that their quality of life is significantly damaged in some cases [...]
The cost of Enzalutamide (Xtandi) in the United States is being challenged by Knowledge Ecology International (KEI), a public interest advocacy group. The average US wholesale price of Xtandi in 2015 was $88 per capsule. That can add up to $129,000 annual cost per man. There are significant issues related to high costs of treatment. [...]